RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) Clinical Trials

43 clinical trials for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation — RECRUITING · PHASE1
• A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients — RECRUITING · NA
• BCL2i CLAG-M in R/R Acute Myeloid Leukemia — RECRUITING · PHASE2
• A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML — RECRUITING · NA
• Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE3
• PHASE I MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF BMS-986497 (ORM-6151) IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME — RECRUITING · PHASE1
• AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION — RECRUITING
• A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS — RECRUITING · PHASE1
• PHASE III RANDOMIZED, DOUBLE-LIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY OF THE ADDITION OF CRENOLANIB TO SALVAGE CHEMOTHERAPY VERSUS SALVAGE CHEMOTHERAPY ALONE IN SUBJECT<75 YEARS OF AGE WITH RELAPSED/REFRACTORY FLT3 MUTATED ACUTE — RECRUITING · PHASE3
• A PHASE 1 FIRST-IN-HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF AMG 427 IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA — RECRUITING · PHASE1
• A PHASE 1/2, MULTICENTER, DOSE-ESCALATION AND EXPANSION STUDY OF COMBINATION THERAPY WITH VENETOCLAX, DARATUMUMAB AND DEXAMETHASONE (WITH AND WITHOUT BORTEZOMIB) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• A PHASE II, MULTI-CENTER, OPEN LABEL, RANDOMIZED STUDY OF RIBAVIRIN AND VISMODEGIB WITH OR WITHOUT AZACYTIDINE IN ACUTE MYELOID LEUKEMIA (AML) — RECRUITING · PHASE2
• A Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia. — COMPLETED · PHASE2
• S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation — NOT_YET_RECRUITING · PHASE1
• Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia — NOT_YET_RECRUITING · PHASE1
• A PHASE 1B STUDY OF THE SAFETY AND PHARMACOKINETICS OF PIVEKIMAB SUNIRINE IN PEDIATRIC SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) — NOT_YET_RECRUITING · PHASE1
• A PHASE 2 TRIAL OF GILTERITINIB IN COMBINATION WITH AZACITIDINE AND VENETOCLAX TO OVERCOME VENETOCLAX RESISTANCE IN PATIENTS WITH RELAPSED/REFRACTORY FLT3-WILD TYPE ACUTE MYELOID LEUKEMIA — NOT_YET_RECRUITING · PHASE2
• A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms — TERMINATED · PHASE1
• Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) — COMPLETED · PHASE1
• AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) — TERMINATED · PHASE1
• A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) — OTHER · PHASE2
• Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia — TERMINATED · PHASE3
• Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia — TERMINATED · PHASE1
• A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) — OTHER · PHASE2
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) — TERMINATED · PHASE1
• Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia — TERMINATED · PHASE1
• A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation — COMPLETED · PHASE1
• Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. — TERMINATED · PHASE1
• Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia — OTHER · PHASE1
• MANAGED ACCESS PROGRAM (MAP) TO PROVIDE ACCESS TO CTL019, FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LARGE B-CELL LYMPHOMA PATIENTS WITH OUT OF SPECIFICATION LEUKAPHERESIS PRODUCT AND/OR MANUFACTURED TISAGENLECLEUCEL OUT OF SPECIFICATION FOR COMMERCIAL RELEASE — NOT_YET_RECRUITING
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE VERSUS PHYSICIAN¿S CHOICE OF VENETOCLAX IN COMBINATION WITH AZACITIDINE OR INTENSIVE CHEMOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH TP53 MUTANT ACUTE MYELOID LEUKEMIA — COMPLETED · PHASE3
• A PHASE 1B DOSE ESCALATION STUDY OF LEMZOPARLIMAB (TJ011133) IN COMBINATION WITH AZACITIDINE AND/OR VENETOCLAX IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) — NOT_YET_RECRUITING · PHASE1
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML — OTHER · PHASE1
• A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN IN COMBINATION WITH EITHER CHEMOTHERAPY OR VENETOCLAX IN THE TREATMENT OF PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS OR SOLID TUMORS — COMPLETED · PHASE1
• PHASE IB/II STUDY OF IDH2 INHIBITOR ENASIDENIB IN COMBINATION WITH BCL2 INHIBITOR VENETOCLAX IN PATIENTS WITH IDH2-MUTATED MYELOID MALIGNANCIES (ENAVEN-AML) — COMPLETED · PHASE1
• A PHASE III RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFICACY OF UPROLESELAN ADMINISTERED WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA — COMPLETED · PHASE3
• PHASE III MULTICENTER OPEN-LABEL RANDOMIZED TRIAL TO EVALUATE EFFICACY AND SAFETY OF CPI-613® (DEVIMISTAT) IN COMBINATION WITH HIGH DOSE CYTARABINE AND MITOXANTRONE (CHAM) COMPARED TO HIGH DOSE CYTARABINE AND MITOXANTRONE (HAM) THERAPY AND CONTROL SUB-GROUPS: COMBINATION OF MITOXANTRONE, ETOPOSIDE AND CYTARABINE (MEC) AND COMBINATION OF FLUDARABINE, CYTARABINE, AND FILGRASTIM (FLAG) IN OLDER PATIENTS (¿ 50 YEARS)WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) — COMPLETED · PHASE3
• CD123 Redirected Autologous T Cells for AML — TERMINATED · PHASE1
• Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia — WITHDRAWN · PHASE1
• A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS67E GIVEN AS MONOTHERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML) — COMPLETED · PHASE1
• A PHASE 3 OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ASP2215 VERSUS SALVAGE CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH FLT3 MUTATION — COMPLETED · PHASE3

Refine this search